Physician profile
Robert Dibianco
NPI 1760444152
$3,211.00
in general payments reported to CMS, 2019-2025
29 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $411 · 2021: $687 · 2022: $243 · 2023: $220 · 2024: $273 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $681.23 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $419.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $284.76 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $266.31 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $209.37 | 2019-2021 | |
| Pfizer INC. | $189.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $124.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.76 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $114.82 | 2019 | |
| Novo Nordisk INC | $84.93 | 2024-2025 | Ozempic, Wegovy |
| Boston Scientific Corporation | $72.08 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $70.63 | 2021-2022 | |
| Edwards Lifesciences Corporation | $66.20 | 2019 | |
| Baxter Healthcare | $58.22 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $56.73 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.14 | 2019-2022 | |
| Esperion Therapeutics, INC. | $44.80 | 2021 | |
| Kestra Medical Technology Services, INC. | $41.89 | 2023 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $36.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.71 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.12 | 2019 | |
| Atricure, INC. | $29.28 | 2024 | |
| Amryt Pharma Holdings Ltd | $20.41 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.03 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $19.27 | 2024 | Arcalyst |
| Abiomed | $18.61 | 2024 | Impella |
| Kiniksa Pharmaceuticals, Ltd. | $14.72 | 2021 | |
| Ge Healthcare | $13.80 | 2025 | |
| Gilead Sciences, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dibianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.